Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• MarketBeat reports an average recommendation of Buy from 10 analysts (1 sell, 6 buy, 3 strong buy) with a mean 1‑year price target of $16.56.
• Analyst views vary widely—recent price targets include $24 (HC Wainwright), $18 (Barclays) and $12 (Leerink, UBS)—reflecting divergent expectations for upside.
• Shares opened at $5.30 (52‑week range $2.85–$7.98); Inventiva is a clinical‑stage biopharma with lead asset lanifibranor (IVA337) in Phase III for NASH, but it reported a Q4 loss (‑$0.16 EPS) and analysts expect about ‑2.08 EPS for the year.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) has been assigned an average recommendation of "Buy" from the ten ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have given a buy rating and three have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $16.5556.

A number of analysts recently weighed in on the stock. Leerink Partners assumed coverage on shares of Inventiva in a report on Monday, January 12th. They issued an "outperform" rating and a $12.00 price target for the company. Barclays assumed coverage on shares of Inventiva in a report on Tuesday, January 27th. They issued an "overweight" rating and a $18.00 price target for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Inventiva in a report on Thursday, January 22nd. UBS Group assumed coverage on shares of Inventiva in a report on Wednesday, January 7th. They issued a "buy" rating and a $12.00 price target for the company. Finally, HC Wainwright set a $24.00 price target on shares of Inventiva and gave the company a "buy" rating in a report on Wednesday, January 28th.

Institutional Trading of Inventiva

Institutional investors have recently bought and sold shares of the business. Creative Planning acquired a new stake in Inventiva during the 2nd quarter worth $32,000. Virtu Financial LLC acquired a new stake in Inventiva during the 4th quarter worth $60,000. XTX Topco Ltd acquired a new stake in Inventiva during the 4th quarter worth $84,000. NewEdge Advisors LLC acquired a new stake in Inventiva during the 3rd quarter worth $116,000. Finally, Cerity Partners LLC acquired a new stake in Inventiva during the 4th quarter worth $93,000. Institutional investors and hedge funds own 19.06% of the company's stock.

Inventiva Price Performance

Shares of Inventiva stock opened at $5.30 on Thursday. The firm has a 50 day simple moving average of $6.08 and a 200 day simple moving average of $5.38. Inventiva has a fifty-two week low of $2.85 and a fifty-two week high of $7.98.

Inventiva (NASDAQ:IVA - Get Free Report) last issued its quarterly earnings results on Saturday, February 14th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $0.01 million for the quarter. On average, analysts expect that Inventiva will post -2.08 EPS for the current year.

Inventiva Company Profile

Inventiva NASDAQ: IVA is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company's core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva's scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company's lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.